Assessment of the Effectiveness, Socio-Economic Impact and Implementation of a Digital Solution for Patients with Advanced Chronic Diseases: The ADLIFE Study Protocol

Borja García-Lorenzo,Ania Gorostiza,Nerea González,Igor Larrañaga,Maider Mateo-Abad,Ana Ortega-Gil,Janika Bloemeke,Oliver Groene,Itziar Vergara,Javier Mar,Sarah N Lim Choi Keung,Theodoros N Arvanitis,Rachelle Kaye,Elinor Dahary Halevy,Baraka Nahir,Fritz Arndt,Anne Dichmann Sorknæs,Natassia Kamilla Juul,Mikael Lilja,Marie Holm Sherman,Gokce Banu Laleci Erturkmen,Mustafa Yuksel,Tim Robbins,Ioannis Kyrou,Harpal Randeva,Roma Maguire,Lisa McCann,Morven Miller,Margaret Moore,John Connaghan,Ane Fullaondo,Dolores Verdoy,Esteban de Manuel Keenoy,ADLIFE Study Group

DOI: https://doi.org/10.3390/ijerph20043152

2023-02-10

Abstract:Due to population ageing and medical advances, people with advanced chronic diseases (ACD) live longer. Such patients are even more likely to face either temporary or permanent reduced functional reserve, which typically further increases their healthcare resource use and the burden of care on their caregiver(s). Accordingly, these patients and their caregiver(s) may benefit from integrated supportive care provided via digitally supported interventions. This approach may either maintain or improve their quality of life, increase their independence, and optimize the healthcare resource use from early stages. ADLIFE is an EU-funded project, aiming to improve the quality of life of older people with ACD by providing integrated personalized care via a digitally enabled toolbox. Indeed, the ADLIFE toolbox is a digital solution which provides patients, caregivers, and health professionals with digitally enabled, integrated, and personalized care, supporting clinical decisions, and encouraging independence and self-management. Here we present the protocol of the ADLIFE study, which is designed to provide robust scientific evidence on the assessment of the effectiveness, socio-economic, implementation, and technology acceptance aspects of the ADLIFE intervention compared to the current standard of care (SoC) when applied in real-life settings of seven different pilot sites across six countries. A quasi-experimental trial following a multicenter, non-randomized, non-concurrent, unblinded, and controlled design will be implemented. Patients in the intervention group will receive the ADLIFE intervention, while patients in the control group will receive SoC. The assessment of the ADLIFE intervention will be conducted using a mixed-methods approach.